Aspraxcel 5000 – L-Asparaginase
L-Asparaginase 5000 IU
Exporter, Distributor Drop shipper to Russia, Brazil, Colombia, Latin America And East Asia
Aspraxcel contains L-Asparaginase, an enzyme-based anticancer therapy used as part of combination chemotherapy regimens for the treatment of Acute Lymphoblastic Leukemia (ALL) and other hematological malignancies. It helps inhibit cancer cell growth by depleting circulating asparagine levels.
|
Contain |
L-Asparaginase 5000 IU |
|---|---|
|
Strength |
5000 IU |
|
Packaging |
1 Vial |
|
Category |
Categories: Anit Cancer |
|
Manufacturer |
Baker & Davis Private Limited |
|
Brand |
Aspraxcel 5000 |
Product Overview
Aspraxcel contains L-Asparaginase, an antineoplastic enzyme indicated as a component of combination chemotherapy regimens for the treatment of certain hematological malignancies. It works by reducing circulating levels of asparagine, an amino acid required for the growth and survival of specific cancer cells, thereby helping inhibit their proliferation.
Aspraxcel is administered under the supervision of qualified healthcare professionals as part of established oncology treatment protocols.
Key Features
- Enzyme-based anticancer therapy.
- Supports established chemotherapy treatment regimens.
- Helps inhibit cancer cell growth through asparagine depletion.
- Manufactured under stringent quality and safety standards.
- Intended for administration in specialized healthcare settings.
- Reliable formulation designed for oncology treatment support.
Mechanism of Action
L-Asparaginase catalyzes the breakdown of circulating L-asparagine into aspartic acid and ammonia. Certain malignant lymphoid cells are unable to synthesize adequate amounts of asparagine and depend on external sources for survival. By depleting circulating asparagine, L-Asparaginase selectively inhibits protein synthesis within these cancer cells, leading to cell death.
Indications
Aspraxcel may be used as part of combination chemotherapy protocols for:
- Acute Lymphoblastic Leukemia (ALL)
- Lymphoblastic Lymphoma
- Other hematological malignancies as determined by the treating oncologist
Benefits
- Supports effective leukemia treatment protocols.
- Established role in pediatric and adult oncology settings.
- Helps improve therapeutic outcomes when used in combination regimens.
- Targets metabolic vulnerabilities of malignant lymphoid cells.
- Contributes to comprehensive cancer management strategies.
Storage
Store according to label instructions and recommended temperature conditions. Protect from excessive heat and direct sunlight.
Pack Information
Available in suitable injectable pack configurations as per market requirements.
Disclaimer
Aspraxcel should be administered only under the supervision of qualified oncology specialists and trained healthcare professionals. Use strictly as prescribed by a registered medical practitioner. Product information may vary depending on local regulatory requirements and approved prescribing information.




